# Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

> **NCT05464810** · EARLY_PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 40 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma
- Invasive Breast Carcinoma

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT05464810
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-02
- **Primary completion:** 2026-04-15
- **Final completion:** 2027-04-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464810, "Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05464810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*